In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1.
about
Molecular targets in arthritis and recent trends in nanotherapyT regulatory cells control susceptibility to invasive pneumococcal pneumonia in miceTransforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptidesTransforming growth factor β1 inhibition protects from noise-induced hearing loss.CD4(+)CD25(+) T regulatory cells inhibit CD8(+) IFN-gamma production during acute and chronic FIV infection utilizing a membrane TGF-beta-dependent mechanism.Density and duration of pneumococcal carriage is maintained by transforming growth factor β1 and T regulatory cellsMucosal immunization with the live attenuated vaccine SPY1 induces humoral and Th2-Th17-regulatory T cell cellular immunity and protects against pneumococcal infection.Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damageProcess of hepatic metastasis from pancreatic cancer: biology with clinical significance.Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.The development and function of regulatory T cells.Regulatory T cells and immune tolerance to tumors.Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'.Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells.Searching for the Achilles Heel of FOXP3Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells.Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B.Immunotherapy of melanoma by GPI-anchored IL-21 tumour vaccine involves down-regulating regulatory T cells in mouse model.Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells?Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells.Transforming growth factor (TGF)-β signalling is increased in rheumatoid synovium but TGF-β blockade does not modify experimental arthritis.Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.Therapeutic strategies against cancer stem cells in human colorectal cancer.Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.Hybrid polymeric-protein nano-carriers (HPPNC) for targeted delivery of TGFβ inhibitors to hepatocellular carcinoma cells.TGF-β antagonist attenuates fibrosis but not luminal narrowing in experimental tracheal stenosis.Regulatory T Cells As Potential Targets for HIV Cure Research.Protective Regulatory T Cell Immune Response Induced by Intranasal Immunization With the Live-Attenuated Pneumococcal Vaccine SPY1 the Transforming Growth Factor-β1-Smad2/3 Pathway
P2860
Q26783466-0DD76E3B-DFC8-4385-8786-74D4F7CDFAAAQ27346256-5C6028C0-BD68-406B-B303-CFFDB939E8E2Q28533494-6D83EC76-6CB3-4497-BF71-276C18742A55Q30414703-D5095A81-C4E9-4BA7-99EF-E058FA025C07Q33714522-12487F29-607C-42ED-95C0-88ECC8E1A8C9Q34479487-2A8C3715-F4F4-49F0-81D5-8642E684B484Q34890164-B3085FE0-BBE1-4321-8C49-47538A4FC36BQ35210203-478232F0-5CEB-4F13-929F-12D98F3E663EQ35739397-55DDA56C-C021-4947-AF15-05B8C5AE71D2Q35828614-6E2BD08B-CE71-46B6-A6D4-45E7676B6EB9Q36083713-FB203C54-517B-435A-9BC8-6703A2801674Q37274250-8BF0A7C4-DB5F-4287-94EC-E8126BBB2DBEQ37599669-FD40A242-AB27-4679-9E3A-FCDE9B58EA39Q37657355-5BB3E1CA-6437-4EFD-9EEE-F648EA632CB5Q37735773-644D298F-A2EE-4172-BA9A-C8D05B84E998Q37967132-54C520E9-20EB-4272-8F91-DD20CA646DC9Q38172210-B5EE167E-7494-41DC-9D7D-3B487FD1E1D3Q38896948-55BC7498-1FAD-4A00-8B84-701EE2B93F98Q39026868-23052542-C71F-4DC9-8CAA-AFC2974E9A33Q39396622-95F796D3-763B-48E0-8D5F-2079BD367D7BQ39665164-D7FE1248-B72D-4396-A136-E9B7909CEDB7Q41916350-D0B96719-514B-4F42-B004-8643292E0090Q42700895-B0B7FB9F-B806-4952-8410-603ADD67938EQ43174362-5D2D5C14-6059-4102-B0C5-7698BA674E9AQ44117426-61A66429-F9BA-40A4-BE16-8B41DCB3950EQ45886137-32100C19-8499-4DC3-BAEC-834AFDA2EFC0Q46971707-3D6F1D38-40C5-470E-BF17-2A44FBCD931DQ47149854-ABD81C7B-8B9E-4F07-BBFF-D1D401DA3C27Q47388658-A917E836-3158-47F1-B1C3-10636185D0D9Q48163498-3F714945-CE67-4E7B-8E3F-32EF2325BBD1Q51320583-C54F040E-9213-4E5A-8266-E1D6C527619AQ52715799-09A11447-488E-455A-9F5D-D118688BC370Q56890395-69EE2704-9F82-4ACA-97D8-2E0751E7C6E4
P2860
In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@en
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@nl
type
label
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@en
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@nl
prefLabel
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@en
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@nl
P2093
P50
P1476
In vitro and in vivo down-regu ...... eptide inhibitor of TGF-beta1.
@en
P2093
Ana Belén López-Vázquez
Diana Llopiz
Francesc Rudilla
Francisco Borrás-Cuesta
Inge Louise Huibregtse
Jacinto López-Sagaseta
Jaione Bezunartea
Javier Dotor
José Ignacio Riezu-Boj
Lucía Gil-Guerrero
P304
P356
10.4049/JIMMUNOL.181.1.126
P407
P577
2008-07-01T00:00:00Z